The invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, cyano, nitro, hydroxy, C(O)O-lower alkyl, S(O)2-lower alkyl, C(O)OCH2-phenyl, OCH2-phenyl, tetrazol-1-yl, phenyl optionally substituted by halogen, or is phenyloxy optionally substituted by halogen, or is benzyl optionally substituted by halogen or is benzyloxy optionally substituted by halogen, wherein the substituents for n> 1 may be the same or different X is -O-(CH2)2-, -O-CHR"-CH2-, -O-CH2-CHR, -O-CR2-CH2-, -(CH2)2-CHR, -CHR-(CH2)2-, -CR"2-(CH2)2-, -CH2-CHR-CH2-, -CH2-CR2-CH2-, -CHR"-O-CH2-, -CH2-O-CH2-, -CR2-O-CH2-, -CF2(CH2)2-, -CR"2-CH2-, -SiR"2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-, for m being 0, 1, 2 or 3 R is lower alkyl, lower alkoxy or lower alkyl substituted by halogen R is lower alkyl or lower alkyl substituted by halogen R2 is hydrogen or lower alkyl Y is aryl, cycloalkyl or heteroaryl n is 1, 2 or 3 or to a pharmaceutically suitable acid addition salt. The compounds disclosed in the present formula (I) may be used for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress- related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinsons disease, neurodegenerative disorders, Alzheimers disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.Cette invention concerne des composés de formule (I), R1 étant hydrogène, alkyle inférieur, alcoxy inférieur, alkyle inférieur substitué par halogène, alcoxy inf
